Biopharma Services And Scentryphar Enter Into A Strategic Partnership Agreement

TORONTO--(BUSINESS WIRE)--BioPharma Services Inc. (BPSI) is pleased to announce it has entered into a partnership and joint venture agreement with Scentryphar, a leading CRO located in Sao Paulo. The partnership will support local and global sponsors looking to bring generic and innovative drugs to the Brazilian market by offering one stop shopping and joint expertise in clinical conduct, bioanalysis, data management, statistics as well as scientific and medical writing.

“I am thrilled with the BPSI – Scentryphar partnership. Our mutual experience with early stage drug development will not only involve healthy volunteers but patients as well. We will work closely with ANVISA officers to strengthen our relationship and share international experience in Scientific and Regulatory affairs”

“We are extremely pleased to partner with Scentryphar to offer generic and Phases I-IV project management for Brazilian submission. This strategic alliance will allow our sponsors to bring products in Brazil in a timely fashion while maintaining high quality standards,” said Mr. Renzo DiCarlo, CEO at BPSI. “We are honoured to partner with BPSI which has a great international reputation in the industry and with many regulatory agencies including US FDA, Health Canada and EMA. Working with BPSI will position both companies as leading CRO's in Brazil,” said Dr. Eduardo Abib Jr., President and Chief Executive Officer at Scentryphar.

“I am thrilled with the BPSI – Scentryphar partnership. Our mutual experience with early stage drug development will not only involve healthy volunteers but patients as well. We will work closely with ANVISA officers to strengthen our relationship and share international experience in Scientific and Regulatory affairs,” said Dr. Fethi Trabelsi, Chief Scientific Officer at BPSI.

About BioPharma Services Inc.: BioPharma Services Inc. is a physician-owned, physician-run, US FDA-inspected, UK MHRA-inspected, and Health Canada-inspected International Contract Research Organization (CRO) which specializes in the conduct of Phase I/IIa clinical trials, including FIM trials, BE studies and bioanalysis, for international pharmaceutical and biotech companies from the US, Canada, Australia and Europe. The company currently has a modern 174-bed clinical facility based in Toronto, Canada, and a new 72-bed clinical facility in Columbia, Missouri. It is privately held and it is headquartered in Toronto, Canada.

About Scentryphar: Scentryphar was created in 2004 by a group of medical professionals. It is strategically located in Campinas, São Paulo close to the best Universities of Brazil, University of São Paulo and University of Campinas. Most of the owners are physicians specialized in clinical pharmacology. Scentryphar has worked with phases I, III, IV and Bioequivalence studies for Brazilian and international companies. It is certified by ANVISA and fully compliant with Laws and Regulations for the Americas. The company has 90 beds in a clinical hospital facility based in Itatiba, Sao Paulo, Brazil.